PFIZER | ALKEM LABORATORIES | PFIZER/ ALKEM LABORATORIES |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 38.5 | - | - | View Chart |
P/BV | x | 6.5 | 7.1 | 91.3% | View Chart |
Dividend Yield | % | 0.5 | 0.6 | 86.4% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
PFIZER Mar-19 |
ALKEM LABORATORIES Mar-16 |
PFIZER/ ALKEM LABORATORIES |
5-Yr Chart Click to enlarge
|
||
High | Rs | 3,840 | 1,589 | 241.7% | |
Low | Rs | 2,080 | 1,232 | 168.8% | |
Sales per share (Unadj.) | Rs | 455.0 | 417.5 | 109.0% | |
Earnings per share (Unadj.) | Rs | 93.8 | 56.3 | 166.6% | |
Cash flow per share (Unadj.) | Rs | 109.4 | 64.7 | 169.0% | |
Dividends per share (Unadj.) | Rs | 22.50 | 12.70 | 177.2% | |
Dividend yield (eoy) | % | 0.8 | 0.9 | 84.4% | |
Book value per share (Unadj.) | Rs | 658.2 | 292.9 | 224.7% | |
Shares outstanding (eoy) | m | 45.75 | 119.57 | 38.3% | |
Bonus/Rights/Conversions | - | - | - | ||
Price / Sales ratio | x | 6.5 | 3.4 | 192.6% | |
Avg P/E ratio | x | 31.6 | 25.1 | 126.0% | |
P/CF ratio (eoy) | x | 27.1 | 21.8 | 124.1% | |
Price / Book Value ratio | x | 4.5 | 4.8 | 93.4% | |
Dividend payout | % | 24.0 | 22.6 | 106.3% | |
Avg Mkt Cap | Rs m | 135,420 | 168,653 | 80.3% | |
No. of employees | `000 | 2.6 | NA | - | |
Total wages/salary | Rs m | 3,238 | 9,171 | 35.3% | |
Avg. sales/employee | Rs Th | 7,911.4 | NM | - | |
Avg. wages/employee | Rs Th | 1,230.9 | NM | - | |
Avg. net profit/employee | Rs Th | 1,630.7 | NM | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 20,815 | 49,915 | 41.7% | |
Other income | Rs m | 1,674 | 1,645 | 101.8% | |
Total revenues | Rs m | 22,489 | 51,561 | 43.6% | |
Gross profit | Rs m | 5,712 | 8,482 | 67.3% | |
Depreciation | Rs m | 714 | 1,006 | 71.0% | |
Interest | Rs m | 73 | 671 | 10.9% | |
Profit before tax | Rs m | 6,599 | 8,451 | 78.1% | |
Minority Interest | Rs m | 0 | -114 | 0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 2,309 | 1,606 | 143.7% | |
Profit after tax | Rs m | 4,291 | 6,731 | 63.7% | |
Gross profit margin | % | 27.4 | 17.0 | 161.5% | |
Effective tax rate | % | 35.0 | 19.0 | 184.1% | |
Net profit margin | % | 20.6 | 13.5 | 152.9% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 27,167 | 27,062 | 100.4% | |
Current liabilities | Rs m | 8,917 | 15,324 | 58.2% | |
Net working cap to sales | % | 87.7 | 23.5 | 372.8% | |
Current ratio | x | 3.0 | 1.8 | 172.5% | |
Inventory Days | Days | 68 | 67 | 102.0% | |
Debtors Days | Days | 30 | 41 | 72.9% | |
Net fixed assets | Rs m | 8,862 | 12,610 | 70.3% | |
Share capital | Rs m | 458 | 239 | 191.3% | |
"Free" reserves | Rs m | 29,656 | 34,490 | 86.0% | |
Net worth | Rs m | 30,113 | 35,027 | 86.0% | |
Long term debt | Rs m | 25 | 1,212 | 2.1% | |
Total assets | Rs m | 39,400 | 54,387 | 72.4% | |
Interest coverage | x | 91.5 | 13.6 | 672.9% | |
Debt to equity ratio | x | 0 | 0 | 2.4% | |
Sales to assets ratio | x | 0.5 | 0.9 | 57.6% | |
Return on assets | % | 11.1 | 13.6 | 81.4% | |
Return on equity | % | 14.2 | 19.2 | 74.1% | |
Return on capital | % | 22.1 | 24.9 | 89.1% | |
Exports to sales | % | 0 | 12.9 | 0.0% | |
Imports to sales | % | 0 | 3.1 | 0.0% | |
Exports (fob) | Rs m | NA | 6,461 | 0.0% | |
Imports (cif) | Rs m | NA | 1,540 | 0.0% | |
Fx inflow | Rs m | 428 | 6,563 | 6.5% | |
Fx outflow | Rs m | 786 | 3,012 | 26.1% | |
Net fx | Rs m | -358 | 3,552 | -10.1% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 978 | 7,259 | 13.5% | |
From Investments | Rs m | 351 | 1,864 | 18.8% | |
From Financial Activity | Rs m | -1,099 | -9,273 | 11.8% | |
Net Cashflow | Rs m | 231 | -150 | -153.9% |
Indian Promoters | % | 0.0 | 66.9 | - | |
Foreign collaborators | % | 63.9 | 0.0 | - | |
Indian inst/Mut Fund | % | 7.5 | 33.1 | 22.7% | |
FIIs | % | 4.9 | 0.0 | - | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 23.7 | 0.0 | - | |
Shareholders | 85,207 | 68,381 | 124.6% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare PFIZER With: ALEMBIC LTD SUN PHARMA PIRAMAL ENTERPRISES FDC LTD. AUROBINDO PHARMA
Compare PFIZER With: MYLAN (US) ADCOCK INGRAM (S. Africa) ACTAVIS (US) TEVA PHARMA (Israel)
| |
On Monday, Indian share markets traded on a volatile note throughout the day and ended flat. The BSE Sensex closed higher by 42 points to end the day at 40,487.
For the quarter ended September 2019, PFIZER has posted a net profit of Rs 2 bn (up 61.0% YoY). Sales on the other hand came in at Rs 6 bn (up 9.1% YoY). Read on for a complete analysis of PFIZER's quarterly results.
For the quarter ended June 2019, PFIZER has posted a net profit of Rs 1 bn (up 22.8% YoY). Sales on the other hand came in at Rs 5 bn (up 6.3% YoY). Read on for a complete analysis of PFIZER's quarterly results.
For the quarter ended March 2019, PFIZER has posted a net profit of Rs 1 bn (up 4.7% YoY). Sales on the other hand came in at Rs 5 bn (up 3.0% YoY). Read on for a complete analysis of PFIZER's quarterly results.
For the quarter ended December 2018, PFIZER has posted a net profit of Rs 1 bn (up 51.2% YoY). Sales on the other hand came in at Rs 5 bn (up 12.5% YoY). Read on for a complete analysis of PFIZER's quarterly results.
Here's an analysis of the annual report of PFIZER for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PFIZER. Also includes updates on the valuation of PFIZER.
More Views on NewsA single stock - Coca Cola, made Buffett billions. Here's your chance to break into the crorepati club with a single smallcap stock investment.
What we can learn from one of the greatest traders to have ever lived.
Should you invest in growth stocks or value stocks to make strong returns in this market?
Vijay and I have decided to team up and bring you a unique offering never seen before in the Indian stock markets.
The lowest hanging fruit for government to raise capital would be to sell off stakes in non-critical PSUs.
More